Pharmaceutical companies are not the only ones out to influence our practice of medicine. Experts, insurance reviewers, advocacy groups, hospital administrators and, of course, patients and their families are just some of the people who would like us to do things a certain way. How can we successfully manage this? Dr. Steven Dubovsky, the Chairman of the Department of Psychiatry at the University of Buffalo joins host Dr. Leslie Lundt to discuss strategies.
Managing the Influence of Others
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Recommended
Details
Presenters
Overview
Pharmaceutical companies are not the only ones out to influence our practice of medicine. Experts, insurance reviewers, advocacy groups, hospital administrators and, of course, patients and their families are just some of the people who would like us to do things a certain way. How can we successfully manage this? Dr. Steven Dubovsky, the Chairman of the Department of Psychiatry at the University of Buffalo joins host Dr. Leslie Lundt to discuss strategies.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
MinuteCE®
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
1.00 credits
<p>Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Cardiology
FINE-HEART Pooled Analysis
<p><span data-teams="true">FINE-HEART Pooled Analysis</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?